|
MechanismROCK2 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects.
This is a single center Phase 1, placebo-controlled, randomized, double blind, first-in-human (FIH), sequential single ascending dose (SAD) study.
100 Clinical Results associated with Graviton, Inc.
0 Patents (Medical) associated with Graviton, Inc.
100 Deals associated with Graviton, Inc.
100 Translational Medicine associated with Graviton, Inc.